The aim of the present study was to develop a method based on gas chromatography-tandem mass spectrometry (GC-MS/MS) to determine and quantify the d-limonene in mouse plasma and tissue samples. This new method was validated for the quantification of d-limonene with the linearity ranges 1.0-1000.0 ng/mL (r  > 0.9952) for plasma samples and 5.0-5000.0 ng/g (r  > 0.9940) for tissue samples. The intra- and inter-day assay of precisions in plasma and tissues were <13.4% and the accuracies were within 91.1-105.8%. In the oral/inhalation administration pharmacokinetics and tissue distribution studies, the main pharmacokinetic parameters were the peak concentration = (97.150 ± 34.450)/(4336.415 ± 1142.418) ng/mL, the area under the curve = (162.828± 27.447)/(2085.721 ± 547.787) h ng/mL and the half-life = (3.196 ± 0.825)/(0.989 ± 0.095) h. The tissue distribution of d-limonene in mice after oral/inhalation administration demonstrated a decreasing tendency in different tissues (liver > kidney > heart > lung > spleen).

Download full-text PDF

Source
http://dx.doi.org/10.1002/bmc.4530DOI Listing

Publication Analysis

Top Keywords

plasma tissues
8
tissue samples
8
determination d-limonene
4
d-limonene mice
4
plasma
4
mice plasma
4
tissues gc-ms/ms
4
gc-ms/ms method
4
method comparison
4
comparison pharmacokinetics
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Actinogen Medical, Sydney, Australia.

Background: Selecting the optimal dose for clinical development is especially problematic for drugs directed at CNS-specific targets. For drugs with a novel mechanism of action, these problems are often greater. We describe Xanamem's clinical pharmacology, including the approach to dose selection and proof-of-concept studies.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Sharp Therapeutics, Pittsburgh, PA, USA.

Background: Progranulin (GRN) plays a critical role in familial frontotemporal dementia (fFTD), where GRN haploinsufficiency leads to reduction in PGRN levels in the brain, resulting in degeneration of neurons in the frontal lobe of brain responsible for personality, language, and behavior. FTD is the most common dementia in people under 60. Sortilin (Sort1), expressed by neurons, endocytoses, and delivers PGRN rapidly to lysosomes for degradation.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

The TT & WF Chao Center for BRAIN and Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX, USA.

Background: Global epidemiological studies involving over nine million participants have shown a 35% lower incidence of Alzheimer's Disease (AD) in older cancer survivors compared to those without a history of cancer. This inverse relationship, consistent across recent studies with methodological controls, suggests that cancer itself, rather than cancer treatments, may offer protective factors against AD. This insight opens avenues for novel therapeutic strategies targeting early AD by harnessing cancer-associated protective factors.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Burke Neurological Institute, Weill Cornell Medicine, White Plains, NY, USA.

Background: Benfotiamine, a prodrug of thiamine, raises blood levels by 50-100 times to achieve pharmacologic effects. It provides a novel therapeutic direction addressing a well-characterized brain tissue thiamine deficiency and related changes in glucose metabolism in AD. BenfoTeam is a seamless phase 2A-2B "proof of concept" (POC), double-blind, placebo-controlled RCT investigating tolerability, safety, and efficacy of benfotiamine, as a first-in-class small molecule treatment for early AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.

Women account for almost two-thirds of Alzheimer's disease (AD) cases, yet evidence significantly less clinical benefit from recently deployed amyloid-lowering therapies. To close this disparity gap, there is an urgent need to identify biological drivers of sex differences in the manifestation and clinical response to AD therapeutics. A recent review of multi-omic studies of AD reported >75% of studies showed female-specific changes at the molecular level (vs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!